🇺🇸 FDA
Patent

US 11851677

Composition and methods for inducing myeloid suppressive cells and use thereof

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 11851677 (Composition and methods for inducing myeloid suppressive cells and use thereof) held by Fate Therapeutics, Inc. expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K35/44, A61K40/10